A revolutionary approach to GLP-1s and obesity care.
Noom Med, our powerful obesity care solution—now with SmartRx—combines biology and psychology to deliver better outcomes and lower overall costs. With a proven 4.1x ROI and SmartRx further enhancing ROI, Noom Med drives long-term success for both individuals and organizations.
Affordable GLP-1 access with a breakthrough pharmacy solution.
While GLP-1s have revolutionized healthcare, they come at a cost. Noom’s SmartRx pharmacy carve-out solution, an enhancement of Noom Med, provides transparent, discounted pricing on GLP-1 medications for weight loss, with the flexibility to set custom copays separate from other covered medications.
Bypass PBM intermediaries for cost-effective, uninterrupted medication access
Access branded GLP-1 medications at reduced prices and decide how to share costs with employees
Ensure rapid access to GLP-1 medications within 5 days to drive increased persistence and better health outcomes
Higher ROI. Better outcomes. Healthier people.
Based in cognitive science, Noom Med delivers maintainable outcomes through evidence-based obesity care that combines sustainable lifestyle changes with medication-assisted weight loss as needed, ultimately maximizing ROI.
Evidence-based protocols
Proven experience showing that while GLP-1 medications are an effective tool for weight management, their efficacy is significantly enhanced when paired with robust lifestyle interventions.
Reducing the yo-yo effect
A structured approach to medication tapering that begins with medication support, and balances medical needs and costs to avoid weight regain as part of the “yo-yo” cycle.
World class behavior change
We utilize our award-winning behavior change program as the foundation of our care model to enhance health outcomes and ensure lasting ROI.
Positive ROI accumulation
A proven track record of delivered, measurable health improvements and cost savings, providing partners with a 4.1X ROI over a three-year period.
Combining mind and medicine, for lasting health outcomes.
Real support leads to real results.
Proven outcomes in 50+ peer-reviewed publications and 10+ academic medical research collaborations.
55%
are expected to start with an alternative to GLP-1s1
1.4X
more weight loss reported when pairing Noom with an early GLP-1 vs a GLP-1 alone2
4.1X
projected ROI in healthcare and cost savings over 3 years3
The proof is in the members.
The Next Evolution in Healthcare Benefits
Chronic disease is getting worse, and healthcare costs keep climbing. Yet most organizations continue to respond the same way, adding…
White Paper
6 Healthcare Trends Shaping the Benefits Landscape
The healthcare benefits landscape is changing fast. Rising pharmacy costs, GLP-1 demand, and a growing shift toward consumer-driven care are…
Blog
Breaking Down the Metabolic Health Domino Effect
Only 6.8% of U.S. adults have optimal metabolic health. That number should stop every benefits leader in their tracks. When…
Blog
The all-in-one solution to healthy living and lower costs.
Bring Noom to your organization today.
- Third-party validated actuarial analysis, October 2024. This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled. ROI may vary based on factors such as company size, employee health profiles, and current healthcare costs.
- Based on a retrospective study of self-reported data of pounds lost for active versus passive users who were offered the Noom program when being prescribed an early stage GLP-1.
- Third-party validated actuarial analysis, October 2024. This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled. ROI may vary based on factors such as company size, employee health profiles, and current healthcare costs.